CCM
SRPT icon

CAAS Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

CAAS Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-44,929
Closed -$5.82M – 895
2022
Q4 		$5.82M Buy
44,929
+195
+0.4% +$22.6K 0.35% 89
2022
Q3 		$4.95M Sell
44,734
-29,326
-40% -$2.96M 0.24% 127
2022
Q2 		$5.55M Buy
74,060
+8,260
+13% +$608K 0.28% 89
2022
Q1 		$5.14M Sell
65,800
-22,630
-26% -$1.73M 0.21% 129
2021
Q4 		$7.96M Buy
88,430
+5,986
+7% +$512K 0.19% 132
2021
Q3 		$7.62M Buy
82,444
+4,700
+6% +$362K 0.15% 143
2021
Q2 		$6.04M Buy
77,744
+24,266
+45% +$1.84M 0.1% 207
2021
Q1 		$3.99M Buy
+53,478
New +$4.93M 0.04% 409

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's SRPT Position: Q1 2023 in Review

CAAS Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 44,929 shares — an estimated $5.82M sold.

CAAS Capital Management first reported a position in SRPT in Q1 2021 and held it in 8 quarters. The position peaked at $7.96M in Q4 2021. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • CAAS Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 44,929 Sarepta Therapeutics shares in Q1 2023, an estimated $5.82M.
  • CAAS Capital Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 8 quarters.
  • CAAS Capital Management's Sarepta Therapeutics position peaked at $7.96M in Q4 2021.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.